Skip to content

Our Impact

pCPA / CGPA Pricing Agreement

In Canada prices of generic prescription medicines are set by provincial and territorial governments and through the pan-Canadian Pharmaceutical Alliance (pCPA) Generics Initiative, which includes Canada’s provinces (excluding Quebec), territories and federal government drug benefit plans. 

At the mid-point of the five-year agreement between CGPA and pCPA that began in April 2018, Canadians have saved nearly two billion dollars. These savings will be matched or exceeded in the second half of the agreement. 

According to the most recent Generics360 report published by the Patented Medicine Prices Review Board (PMPRB), prices of generic prescription medicines in Canada are five percent below prices in comparator countries.  

Impact

pan-Canadian Tiered Pricing
Framework (TPF)

pan-Canadian Molecules

Since April 1, 2018, sixty-seven (67) of the most commonly prescribed generic prescription medicines are available at up to a 90 percent discount off the price of the brand-name versions. These medicines are used by millions of Canadians every day to treat conditions such as high blood pressure, high cholesterol, and depression. The pan-Canadian molecules are not part of the Tiered Pricing Framework process but rather are set at fixed prices.